Print

Genmab A/S (GEN.CO) Announces Preliminary Safety and Efficacy Data for Daratumumab  
12/12/2011 9:55:29 AM

COPENHAGEN, Denmark, Dec. 11, 2011 (GLOBE NEWSWIRE) --Genmab A/S (Copenhagen:GEN) announced today encouraging preliminary safety and efficacy data from the first Phase I/II clinical study of daratumumab (HuMax(r)-CD38) in multiple myeloma. A 49%, 55%, and 61% reduction in the serum M-component was observed in the three patients treated at the highest dose level examined so far (4 mg/kg of daratumumab). The serum M-component is an abnormal protein produced by the cancerous plasma cells and is a direct marker for tumor activity. Reduction in the serum M-component is a key factor for response evaluations in multiple myeloma. The observed level of reduction therefore indicates that daratumumab was clinically active in these multiple myeloma patients.
//-->